The cost-effectiveness of HLA-B*5801 screening to guide initial urate-lowering therapy for gout in the United States.
Sign Up to like & getrecommendations! Published in 2017 at "Seminars in arthritis and rheumatism"
DOI: 10.1016/j.semarthrit.2016.10.009
Abstract: OBJECTIVE Positive HLA-B*5801 carriers are at greater risk of experiencing rare but severe allopurinol hypersensitivity syndrome (AHS) [i.e., Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN)]; however, HLA-B*5801 prevalence and AHS risk vary by race/ethnicity.… read more here.
Keywords: cost effectiveness; united states; hla 5801; hla ... See more keywords
Diagnostic utility of HLA‐B*5801 screening in severe allopurinol hypersensitivity syndrome: an updated systematic review and meta‐analysis
Sign Up to like & getrecommendations! Published in 2017 at "International Journal of Rheumatic Diseases"
DOI: 10.1111/1756-185x.13143
Abstract: Despite many studies suggesting an association between human leukocyte antigen (HLA)‐B*5801 and allopurinol‐induced toxic epidermal necrolysis (TEN) and Stevens‐Johnsons syndrome (SJS), the evidence of association in different populations and the degree of association remain uncertain. read more here.
Keywords: screening severe; hla; 5801 screening; diagnostic utility ... See more keywords